Dr Dinesh Pendharkar highlights how CAR T–cell therapy is reshaping cancer care in India by equipping the immune system with ...

In the BRIGHT study, bendamustine plus rituximab was evaluated as a first-line treatment for indolent non-Hodgkin lymphoma or mantle cell lymphoma compared with a standard rituximab-chemotherapy ...

The Phase II trial will compare progression-free survival in lung cancer patients treated according to their molecular subtypes.

The bispecific antibody market is experiencing rapid growth, primarily driven by the increasing prevalence of complex chronic diseases, such as cance ...

The FDA approved Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.